Multiple Myeloma: Bortezomib, Lenalidomide, and Dexamethasone Intensol
López Anglada1*, Juan Bargay2, Isidro Jarque2, Ana González3, Bruno Paiva4
1Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
3Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
4Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
Correspondence to: López Anglada, Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain. E-mail: lopez_anglada@gmail.com
Received: March 09, 2023; Accepted: March 25, 2023; Published: April 02, 2023
Citation: Anglada L, Bargay J, Jarque I, González A, Paiva B. Multiple Myeloma: Bortezomib, Lenalidomide, and Dexamethasone Intensol. J Clin Oncol Cancer Res . 2023;1(1):13-21
Copyright: © 2023 Anglada L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
